Dosing logistics and patient convenience drove updates in immunotherapy delivery. In small-cell lung cancer, subcutaneous tarlatamab (from the DeLLphi-308 Phase 1b study) showed safety and early activity, pointing to a less burdensome administration route for patients with extensive-stage disease after standard treatments. A separate DeLLphi-309 report suggested longer gaps between tarlatamab doses may maintain benefits while improving flexibility. Together, the readouts indicate the field is moving beyond efficacy alone toward regimen design that balances clinical outcomes with real-world administration.